| Results | Prevalence, 0.3% | Prevalence, 1% | Prevalence, 5%-15% (High Risk) |
|---|---|---|---|
| Persons screened, n | 10,000 | 10,000 | 10,000 |
| Persons identified as HIV-positive, n | 30 | 100 | 500-1500 |
| Patients receiving test results, n | 24-28 | 79-93 | 400-1400 |
| Partners identified as HIV-positive, n | 2-6 | 6-21 | 32-320 |
| Total HIV-positive patients identified, n | 26-34 | 85-114 | 426-1720 |
| Patients with CD4 cell count < 0.200 × 109 cells/L, n | 3-15 | 10-49 | 51-740 |
| Cases of clinical progression or deaths prevented over 3 y with HAART, n | 0.7-8.2 | 2-28 | 12-410 |
| NNSB to prevent 1 clinical progression or death over 3 y | 1210-13,800 | 360-4140 | 24-830 |
| NNTB with HAART to prevent 1 clinical progression or death over 3 y | 1.8 (95% CI, 1.5-2.2) | 1.8 (95% CI, 1.5-2.2) | 1.8 (95% CI, 1.5-2.2) |
| NNCB, NNSB, or NNTB to prevent 1 horizontal transmission over 3 y | Unable to calculate | Unable to calculate | Unable to calculate |
| Cardiovascular or cerebrovascular events caused by HAART over 3 y, n | 0.006-0.6 | 0.02-2 | 0.1-30 |
| NNSH to cause 1 cardiovascular or cerebrovascular event over 3 y | 16,900-1,580,500 | 5100-474 400 | 340-95 000 |
| NNTH with HAART to cause 1 cardiovascular or cerebrovascular event over 3 y | 69 (95% CI, 21-257) | 69 (95% CI, 21-257) | 69 (95% CI, 21-257) |
aNotes: NNCB = number needed to counsel for benefit; NNSB = number needed to screen for benefit; NNSH = number needed to screen for harm; NNTB = number needed to treat for benefit; NNTH = number needed to screen for harm.